Cost effectiveness of Gene Expression Profiling in Patients with Early-Stage Breast Cancer in a Middle-Income Country, Turkey: Results of a Prospective Multicenter Study
EUROPEAN JOURNAL OF BREAST HEALTH, cilt.15, sa.3, ss.183-190, 2019 (TRDizin)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 15 Sayı: 3
- Basım Tarihi: 2019
- Doi Numarası: 10.5152/ejbh.2019.4761
- Dergi Adı: EUROPEAN JOURNAL OF BREAST HEALTH
- Derginin Tarandığı İndeksler: TR DİZİN (ULAKBİM)
- Sayfa Sayıları: ss.183-190
- Anahtar Kelimeler: Early breast cancer, genetic profiling, oncotype-Dx, cost, markov model, QUALITY-OF-LIFE, RECURRENCE SCORE, CHEMOTHERAPY, TAMOXIFEN, ASSAY, RISK
- Acıbadem Mehmet Ali Aydınlar Üniversitesi Adresli: Hayır
Özet
Objective: Breast cancer is a heterogenous disease, and genetic profiling helps to individualize adjuvant treatment. The Oncotype DX is a validated test to predict benefit of adjuvant systemic treatment. The aims of this study are to determine the costs of chemotherapy in government hospitals in Turkey and evaluate the cost-effectiveness of the Oncotype DX from the national insurance perspective.